FDA grants first coronavirus clearance for sample pooling to Quest

By LabPulse.com staff writers

July 20, 2020 -- The U.S. Food and Drug Administration has granted Quest Diagnostics the first emergency use authorization for a SARS-CoV-2 molecular diagnostic for testing pooled samples.

The Quest SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR) test was granted clearance on July 18 for use in testing specimens for up to four individuals. It was previously granted clearance for testing individual samples in March.

Sample pooling allows more people to be tested and uses fewer testing resources. If a pool of specimens tests positive, each sample is then tested again individually. The FDA issued guidance on pooling this month and the method has become an important part of testing strategy for the White House Coronavirus Task Force as a means of boosting throughput. Quest has reported challenges in meeting demand for testing with quick turnaround in recent weeks.

"The FDA continues to work with a number of diagnostic test developers to facilitate new approaches and get additional tests to more Americans more quickly," the agency said in a statement.

FDA provides guidance on pooling to boost coronavirus test throughput
The U.S. Food and Drug Administration (FDA) has clarified guidance on the validation of pooled coronavirus testing, in a bid to pave the way for submission...
Point-of-care COVID-19 antibody tests should not be used, experts advise
Point-of-care antibody tests for COVID-19 have performance issues and should not be used beyond research purposes, according to a systematic review and...
More stool PCR testing likely needed in COVID-19 patients
Viral shedding from SARS-CoV-2 is being reported in stool samples, underscoring the need for better monitoring, including more testing, according to a...
COVID-19 testing presents learning curve for all involved
For most aspects of the COVID-19 diagnostic testing process, there has been a learning curve for all involved. But creative solutions have been emerging...
ESMO: Blood test predicts relapse risk in colon cancer
A blood test showed potential for predicting relapse in nonmetastatic colon cancer patients and for reducing unnecessary treatments in a large study reported...

Copyright © 2020 LabPulse.com

Last Updated eh 7/20/2020 4:09:43 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current